HomeBUSINESS
BUSINESS

China FDA Puts Lenvima on Priority Review for HCC
(Dec.28.2017)

Eisai said on December 27 that its cancer drug Lenvima (lenvatinib) was granted a priority review status by the China FDA for the treatment of hepatocellular carcinoma (HCC) ...
(LOG IN FOR FULL STORY)